AQST vs BCYC

AQST exhibits severe financial distress despite modest revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health. The company reports massive negative profitability metrics, including a -188.09% profit margin and -33.92% ROA, with no meaningful earnings or cash flow generation. Insider selling totaling $1.86M over six months, including significant sales by top executives, signals deep skepticism about future prospects. While the stock trades below its 52-week high and has a strong analyst consensus, the lack of intrinsic value support and deteriorating earnings trends undermine long-term viability. The absence of a valid Altman Z-Score and Graham Number further limits fundamental valuation reliability.

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite a remarkable 338.5% year-over-year revenue growth and strong analyst target price of $21.50 implying 210% upside, the company continues to report deep operating losses (-558.64% operating margin), deteriorating earnings (YoY EPS growth of -18.1%), and inconsistent earnings surprises, with only 1 out of the last 4 quarters beating estimates. High valuation multiples (Price/Sales of 17.01) contrast with negative profitability and weak insider sentiment, while recent insider selling adds downward pressure. Although the balance sheet appears strong with a current ratio of 10.66 and minimal debt, the lack of profitability and cash flow transparency limits confidence in sustainable recovery.